Humacyte, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HUMA research report →
Range $1 – $2
Price Chart
About the company
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields.
- CEO
- Laura E. Niklason
- IPO
- 2020
- Employees
- 184
- HQ
- Durham, NC, US
Get TickerSpark's AI analysis on HUMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $123.73M
- P/E
- -1.09
- Fwd P/E
- 14.85
- PEG
- 0.01
- P/S
- 58.09
- P/B
- 7.70
- EV/EBITDA
- -1.80
- Div Yield
- 0.00%
- Gross Margin
- -549.75%
- Op Margin
- -4602.92%
- Net Margin
- -3955.05%
- ROE
- -591.73%
- ROIC
- -109.40%
Latest fiscal year · YoY change
- Revenue
- $2.04M+0.0%
- Gross Profit
- $-15,009,000-108.7%
- Op Income
- $-107,437,000
- Net Income
- $-40,833,000+72.5%
- EPS
- $-0.26+79.4%
- OCF Growth
- -7.1%
- FCF Growth
- -6.3%
- 52W High
- $1.53
- 52W Low
- $0.34
- 50D MA
- $0.49
- 200D MA
- $0.77
- Beta
- 2.68
- RSI (14)
- 45
- Avg Volume
- 5.41M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Humacyte said Symvess sales accelerated sharply in Q3, the dialysis sBLA remains on track for November filing, and first-in-human CABG testing has begun.· November 10, 2026
- Symvess sales rose 151% sequentially to slightly over $1 million in Q3, with hospital accounts ordering increasing from 34 to 49.
- Management said October Symvess sales reached $800,000 and expects Q4 sales to at least double Q3.
- The company plans to file the sBLA for ATEV in dialysis access later this month; FDA acceptance would be expected in January.
- Humacyte initiated its first human Phase IIa study of CTEV in CABG and is now screening patients.
- Cash was $64.9 million at September 30, 2026, and operating cash burn declined versus last year and sequentially due to cost cuts and lower production costs.
Humacyte reported third-quarter 2026 Symvess commercial sales of $1 million, up from $0.4 million in Q2 2026 and $0.7 million in Q3 2025. For the first nine months of 2026, Symvess sales were $1.9 million versus $1 million a year earlier. Cost of goods sold was $1.4 million in Q3 2026 versus $0.3 million in Q3 2025; research and development expense was $14.1 million versus $17.3 million; general and administrative expense was $9.0 million versus $7.6 million; and net loss was $15.5 million versus $17.5 million. Cash, cash equivalents and restricted cash totaled $64.9 million at September 30, 2026. Looking ahead, management said Q4 Symvess sales should at least double Q3, October sales were already $800,000, and by year-end it expects at least 20 new hospitals to order through its network. For the dialysis access sBLA, management said filing is planned for November, FDA acceptance is expected in January, and if priority review is granted the PDUFA date could be in May with a launch soon thereafter; without priority review, PDUFA would shift to September and launch would follow after that.
Laura Niklason framed the quarter as a potential inflection point, saying the company has made substantial progress across commercial execution, dialysis access, and CABG development. Her tone was notably upbeat, emphasizing that the remodeled commercial structure is already working and that the company is building toward value creation in the months and years ahead. She also highlighted the strength of the dialysis data package and the start of the first human CABG study as major strategic milestones.
Dale Sander focused on improving operating discipline and the financial impact of the commercialization ramp. He said Q3 Symvess revenue was $1 million, COGS was $1.4 million, R&D was $14.1 million, G&A was $9.0 million, and net loss was $15.5 million; for the first nine months, net loss was $70.0 million and Symvess sales were $1.9 million. He also said cash used in operations fell to $15.0 million in Q3 from $23.9 million a year earlier, and to $62.1 million for the first nine months from $78.9 million, largely due to lower inventory production costs and cost-reduction measures. On margins, he noted unused production capacity is still flowing through COGS in Q4, but said that should ease in 2027 as production scales.
Analysts focused on how durable the Symvess adoption surge is, what the introductory pricing means for ASP, whether gross margin can turn positive in Q4, and how the company is preparing for dialysis commercialization. Management said the Q3 improvement was driven by new commercial leadership, revamped marketing and training, and introductory pricing to get hospitals started, and that the same vascular surgeons who use Symvess today often also do dialysis access. On dialysis, Laura Niklason said the key timing variable is whether FDA grants priority review after the November filing; that decision would determine whether launch could occur around June or be pushed to after September. Questions also touched on trauma, international expansion, and real-world case studies; management said adoption in trauma is still expanding organically, Israel remains under review, and physician case presentations are expected, including at VEITH.
The call showed clear commercial momentum, with Symvess sales more than doubling sequentially and hospital ordering expanding materially. Management sounded increasingly confident that the rebuilt commercial team, pricing strategy, and physician education efforts are taking hold, while the dialysis sBLA and CABG program create additional near- and medium-term catalysts.
Gross margin is still pressured by unused production capacity, and management said that issue is likely to continue in Q4 before improving in 2027. The dialysis launch timeline still depends on FDA acceptance and whether priority review is granted, creating a meaningful timing split between a possible June launch and a later launch after September. The company also remains cash constrained, with management saying the BioVascular Pancreas will likely receive more resources next year when there is more daylight around cash flow.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.3%
- Shares Outstanding
- 277.80M
- Float Shares
- 250.79M
of shares held by institutions
174 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HUMA, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Thomas Hawley TubervilleSenate · AL | Buy | Mar 21, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | Mar 21, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | Mar 21, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | Mar 21, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | May 3, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | May 3, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Apr 30, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | Mar 21, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | Feb 12, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Jan 19, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | Jul 25, 23 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | Mar 30, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 10.96M | ▲ 856.43K |
| Vanguard Group Inc | 8.42M | ▲ 896.92K |
| Antipodes Partners Ltd | 8.26M | ▼ 1.85M |
| Alyeska Investment Group, L.P. | 6.02M | ▲ 6.02M |
| Davidson Kempner Capital Management LP | 5.00M | ▲ 5.00M |
| Blackrock, Inc. | 4.57M | ▼ 274.30K |
| Great Point Partners LLC | 3.75M | 0 |
| Ubs Group AG | 3.01M | ▲ 163.78K |
| Marshall Wace, Llp | 3.00M | ▲ 2.81M |
| Geode Capital Management, LLC | 2.68M | ▲ 491.25K |
| Aqr Capital Management LLC | 2.60M | ▲ 672.44K |
| Millennium Management LLC | 1.91M | ▲ 1.80M |
Held by 54 ETFs
Biggest fund positions in HUMA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 26 | COWARD D SCOTT | other | 125,000 |
| Oct 6, 26 | Kuznik Paul Brian | other | 125,000 |
| Sep 22, 26 | Kuznik Paul Brian | other | 0 |
| Sep 22, 26 | Kuznik Paul Brian | other | 0 |
| Sep 22, 26 | COWARD D SCOTT | other | 0 |
| Sep 14, 26 | Jones Keith Anthony | buy | 10,000 |
| Aug 20, 26 | Jones Keith Anthony | buy | 10,000 |
| Aug 17, 26 | Jones Keith Anthony | buy | 30,000 |
| Jun 11, 26 | Windham-Bannister Susan Richards | other | 80,000 |
| Jun 11, 26 | Constantino Michael T. | other | 80,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HUMA coverage
Recent articles, reports, and earnings notes.
No research on HUMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HUMA report →Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
globenewswire.com · Nov 19
Humacyte, Inc. (NASDAQ:HUMA) Stock Has Average Price Target of $4.48 According to Analysts
defenseworld.net · Nov 19
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
globenewswire.com · Nov 16
Humacyte Q3 Earnings Call Highlights
defenseworld.net · Nov 13
Five Presentations, One Leading Innovation: Humacyte's Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
globenewswire.com · Nov 11
Humacyte, Inc. (HUMA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Humacyte Q3 Earnings Call Highlights
marketbeat.com · Nov 10
Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.